Brief ReportsTreatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions☆
References (5)
- et al.
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
Nat Med
(1995) - et al.
Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
Clin Exp Immunol
(1994)
There are more references available in the full text version of this article.
Cited by (221)
Psoriasis Induced by Biological Therapy
2021, Reumatologia ClinicaGranuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways
2020, Journal of the American Academy of DermatologyTumor Necrosis Factor Inhibitors
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionExpanding the applications of microneedles in dermatology
2019, European Journal of Pharmaceutics and BiopharmaceuticsHow Can We Promote Physician-Directed Research in Complex Medical Dermatology?
2016, Journal of Investigative Dermatology
- ☆
Reprint requests: Alice B. Gottlieb, MD, PhD, Clinical Research Center, One Robert Wood Johnson Place, Box 19, New Brunswick, NJ 08903. E-mail: [email protected].
Copyright © 2000 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.